What happened
On November 12, 2026, Health Canada published an advisory about injectable and capsule-format peptide products offered by Sage & Summit Wellness Co. in Ottawa. According to the advisory, an enforcement seizure followed a consumer complaint concerning products sold in-store and online.
Health Canada reported that laboratory testing detected bacteria in one seized injectable peptide product. The agency warned that contaminated injections can cause severe infections and told consumers not to buy or use unauthorized peptide products. This summary is based on the official public notice, not an independent investigation conducted by this publication.
Which product names appeared in the notice?
The notice listed several labels among affected unauthorized products, including BPC-157, MOTS-C, retatrutide, tesamorelin, KLOW and other peptide combinations. Being named in the notice indicates the context of this enforcement event; it does not establish that every product anywhere bearing a related scientific name is identical.
The central issue is the unauthorized status and safety concerns of the seized products, not a recommendation to compare or seek substitutes.
Why contamination matters
Sterility is a distinct quality requirement for injectables. A chemical-identity or purity assay alone does not establish that a product is free from viable microorganisms or other harmful contaminants.
Health Canada warned about symptoms including fever, chills, redness or swelling following injection and advised immediate medical attention for potentially concerning symptoms. People who have used an unauthorized product and feel unwell should seek professional medical advice.
A lab-report screenshot on a retail website may be relevant to a narrowly defined analytical claim, but it cannot replace the broader product controls required for medicines.
Research labels are not a legal shortcut
The November advisory says some seized products carried “For Research Purposes Only” wording. Health Canada explained that such wording does not make products legal or exempt from applicable requirements, and does not mean they were manufactured to human-use standards.
This should change how readers interpret vendor marketing. A product’s intended market or web presentation cannot substitute for authorization and verified quality systems.
How this relates to earlier warnings
The November 12 advisory followed an earlier November 6 warning about unauthorized injectable peptide and non-peptide drugs after contamination findings and seizures linked to another source. The two notices concern separate events; readers should examine each original advisory for its own facts.
Together they show why exact identification, source documents and dated regulatory information matter more than generic claims about an entire ingredient category.
Our editorial response
We are linking this advisory to relevant compound dossiers and Canadian regulatory guides, and maintaining dated source checks on the directory. A vendor profile is an independent information record, not a medical safety certification.
If Health Canada updates, corrects or replaces the advisory, the article should be revised and the original notice consulted for the most current instructions.